Remed KRX:302550KOSDAQ
리메드 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, Remed reported revenue of ₩7.4bn, up 32.7% year on year, and operating profit of ₩945m. Remed (리메드) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Major holder adding Share pledge Screener
Remed quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩7.4bn | +32.7% | ₩945m | ₩272m |
| Q1 2026 | ₩7.2bn | +11.4% | ₩684m | ₩1.0bn |
| Q4 2025 derived | ₩6.7bn | +3.9% | ₩51m | −₩204m |
| Q3 2025 | ₩5.8bn | -3.7% | ₩272m | ₩168m |
| Q2 2025 | ₩5.6bn | -28.4% | ₩25m | −₩217m |
| Q1 2025 | ₩6.4bn | +21.2% | ₩377m | ₩218m |
| Q4 2024 derived | ₩6.4bn | +49.4% | −₩250m | ₩3.1bn |
| Q3 2024 | ₩6.0bn | +44.8% | ₩124m | ₩3.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Remed top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Remed news Korean headlines
No articles yet.